Denali Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
All right. Good morning. Looking forward to today's discussion around the work we're doing here at Denali Therapeutics. I'm Ryan Watts. I'm the CEO of Denali Therapeutics. And for those of you that have joined the call today, there will be a slide deck distributed on the webcast, and I ask that you look to the bottom left-hand corner for the slide numbers. I will reference those slide numbers as I go through today's presentation.
So as a reminder, Denali -- starting with Slide 2, Denali was founded to work on neurodegenerative diseases, and our purpose is to defeat degeneration. You'll see on this slide, basically 4 major areas: rare neurodegenerative diseases, ALS, Parkinson's and Alzheimer's. And in fact, we have either ongoing or completed clinical trials in all 4 of these areas. I will share with you today some of the data that we've generated in Parkinson's disease as well as an emphasis on our approach for engineering large molecules for rare neurodegenerative diseases and also beyond in Alzheimer's disease
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |